XSHE
000919
Market cap603mUSD
Oct 09, Last price
6.67CNY
1D
2.62%
1Q
8.81%
Jan 2017
-50.70%
Name
Jinling Pharmaceutical Co.
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jinling Pharmaceutical Company Limited is a Chinese enterprise specializing in the manufacture and distribution of a diverse range of pharmaceutical products. Its key offerings include the Mailuoning injection, prescribed for the management of numerous vascular and thrombotic conditions such as thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and its sequelae, multiple forms of arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, and thrombophlebitis. The company also provides ferrous succinate tablets for the prevention and treatment of iron deficiency anemia, alongside lentinan injection used in the therapy of malignant tumors. Furthermore, Jinling Pharmaceutical offers medical health care services. The firm's operations are primarily based in Nanjing, China.
Key people
Chunmin Li
Chairman of the Board · since 2017
Yutang Liang
President · since 2017
Yang Wang
Finance Director, Vice President · since 2017
Wei Guo Tang
Executive Vice President · since 2011
Jianbiao Yin
Vice President · since 2011
Jinbao Chen
Director · since 2006
Zhongxiang Ni
Director · since 2011
Weimin Xu
Director · since 2012
Yinhua Zhou
Director · since 2004
Independent Director · since 2008
Rong Shao
Independent Director · since 2008
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||